Security
Rafael Holdings, Inc. Class B Common Stock · RFL
RFLNYSECommon stockCurrentCIK 1713863Updated Oct 6, 2026
RFL price & chart
Loading TradingView…
NYSE:RFL on TradingView ↗About the company
Rafael Holdings, Inc. is a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage companies that develop pharmaceuticals and medical devices. Our lead candidate is Trappsol® Cyclo™, and we have completed a pivotal Phase 3 study in NPC and are preparing for a planned NDA submission later this year. Niemann-Pick Disease Type C (“NPC”) is a rare, fatal and progressive genetic disorder. We also hold interests in other clinical-stage and early-stage pharmaceutical development companies and an orthopedic-focused medical device company.
In the news
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results ↗
Seeking Alpha
Rafael Holdings: A Coin Flip With A Second Binary Attached - Hold ↗
Rafael Holdings, Inc. (RFL) Discusses Topline Results of Phase III TransportNPC Study of Trappsol Cyclo in Niemann-Pick Disease Type C Transcript ↗
Rafael Holdings: The Second Half Of Calendar 2026 Could Define This Company Forever ↗
Recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
Regulation FD Disclosure
Items 7.01, 9.01
4 filing
10-Q filing
Show 4 more recent filings
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
4 filing
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 114,109,000Source | 96,832,000Source | 98,829,000Source | 118,320,000Source |
| Property, Plant and Equipment, NetUSD | 1,596,000Source | 2,120,000Source | 1,695,000Source | 1,770,000Source |
| GoodwillUSD | 19,939,000Source | 3,050,000Source | — | — |
| Intangible Assets, Net (Excluding Goodwill)USD | 994,000Source | 1,847,000Source | — | — |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 52,769,000Source | 2,675,000Source | 21,498,000Source | 26,537,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 627,000Source | 426,000Source | 213,000Source | — |
| Inventory, NetUSD | 281,000Source | — | — | — |
| Assets, CurrentUSD | 56,714,000Source | 72,502,000Source | 82,941,000Source | 108,347,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 786,000Source | 430,000Source | 914,000Source | 4,621,000Source |
| Other Assets, NoncurrentUSD | 34,000Source | 35,000Source | 9,000Source | 1,387,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 15,738,000Source | 10,574,000Source | 2,200,000Source | 21,114,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | — | — | — | 8,000Source |
| Additional Paid in CapitalUSD | — | — | — | 262,023,000Source |
| Retained Earnings (Accumulated Deficit)USD | -232,263,000Source | — | -167,333,000Source | -165,457,000Source |
| Stockholders' Equity Attributable to ParentUSD | 94,391,000Source | 82,185,000Source | 100,293,000Source | 100,515,000Source |
| Additional Paid in Capital, Common StockUSD | 322,161,000Source | — | 264,010,000Source | — |
| Liabilities and EquityUSD | 114,109,000Source | 96,832,000Source | 98,829,000Source | 118,320,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 11,600,000Source | 7,514,000Source | 2,145,000Source | 21,026,000Source |
| Accounts Payable, CurrentUSD | 6,893,000Source | 2,556,000Source | 333,000Source | 564,000Source |
| Deferred Income Tax Liabilities, NetUSD | 138,000Source | 73,000Source | — | — |
| Other Liabilities, NoncurrentUSD | 27,000Source | 5,000Source | 55,000Source | 88,000Source |
| Stockholders' Equity Attributable to Noncontrolling InterestUSD | 3,980,000Source | 4,073,000Source | -3,664,000Source | -3,309,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 3,304,000Source | 1,798,000Source | 763,000Source | 1,875,000Source |
| AOCI, Debt Securities, Available-for-sale, Adjustment, after TaxUSD | 358,000Source | 111,000Source | -353,000Source | -63,000Source |
| Deferred Tax Liabilities, NetUSD | 138,000Source | — | — | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -30,643,000Source | -65,003,000Source | -2,215,000Source | -142,377,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | — | — | 78,000Source | 72,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 2,123,000Source | 2,296,000Source | 2,188,000Source | -917,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts ReceivableUSD | 151,000Source | — | — | — |
| Increase (Decrease) in InventoriesUSD | 11,000Source | — | — | — |
| Deferred Income Tax Expense (Benefit)USD | -165,000Source | -97,000Source | — | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -18,924,000Source | -7,802,000Source | -10,886,000Source | -26,079,000Source |
| Cash flows from investing activities: | ||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | 2,709,000Source | -1,099,000Source | — | — |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | 44,035,000Source | -10,820,000Source | 21,211,000Source | -63,796,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 4,000Source | 143,000Source | — | — |
| Cash flows from financing activities: | ||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | 215,000Source | — | — | 75,000Source |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 24,830,000Source | -179,000Source | -15,218,000Source | 103,864,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 50,094,000Source | -18,823,000Source | -5,039,000Source | 13,683,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 52,769,000Source | 2,675,000Source | 21,498,000Source | 26,537,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 153,000Source | -22,000Source | -146,000Source | -306,000Source |
| Additional Financial Items | ||||
| AmortizationUSD | — | — | — | 472,000Source |
| Share-based Payment Arrangement, ExpenseUSD | 2,123,000Source | 2,296,000Source | 2,188,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | 0Source | 472,000Source |
| Amortization of Intangible AssetsUSD | 142,000Source | 88,000Source | — | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | -45,000Source |
| Debt Securities, Realized Gain (Loss)USD | 178,000Source | 1,772,000Source | — | — |
| DepreciationUSD | — | — | — | 1,000Source |
| Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of TaxUSD | — | — | 6,784,000Source | -1,830,000Source |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | — | — | -306,000Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 334,000Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 25,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -53,000Source | -42,000Source | -5,000Source |
| Gain (Loss) on Disposition of Real Estate, Discontinued OperationsUSD | — | — | — | -501,000Source |
| Gain (Loss) on InvestmentsUSD | — | -46,000Source | — | — |
| Gain (Loss) on Sale of PropertiesUSD | — | — | 1,195,000Source | — |
| Gain (Loss) on Disposition of Property Plant EquipmentUSD | -81,000Source | 27,000Source | — | — |
| General and Administrative ExpenseUSD | 13,781,000Source | 8,854,000Source | 8,932,000Source | 17,270,000Source |
| GoodwillUSD | 19,939,000Source | 3,050,000Source | — | — |
| Goodwill, Impairment LossUSD | 3,050,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -65,003,000Source | -8,693,000Source | -140,547,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -8,693,000Source | -140,547,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 6,478,000Source | -1,830,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 1,830,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -575,000Source |
| Income Tax Expense (Benefit)USD | -2,553,000Source | -2,680,000Source | -255,000Source | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 1,772,000Source | 154,000Source | — |
| Marketable Securities, Unrealized Gain (Loss)USD | — | — | 33,000Source | -45,000Source |
| Net Income (Loss) Attributable to ParentUSD | -30,520,000Source | -34,410,000Source | -1,876,000Source | -140,547,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -123,000Source | -30,593,000Source | -339,000Source | -17,719,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -34,410,000Source | -1,876,000Source | -124,658,000Source |
| Operating Lease, Impairment LossUSD | — | — | — | 0Source |
| Other Depreciation and AmortizationUSD | — | — | — | 1,317,000Source |
| Other Nonoperating Income (Expense)USD | 310,000Source | — | — | — |
| Payments for Repurchase of WarrantsUSD | 3,600,000Source | — | — | — |
| Proceeds from Issuance of Common StockUSD | 25,001,000Source | — | — | 99,170,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | 28,500,000Source |
| Realized Investment Gains (Losses)USD | — | -46,000Source | 309,000Source | — |
| Unrealized Gain (Loss) on DerivativesUSD | — | 1,191,000Source | — | 31,850,000Source |
| Unrealized Gain (Loss) on InvestmentsUSD | — | — | 33,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 917,000Source | 637,000Source | 279,000Source | 410,000Source |
| Cost of Goods and Services Sold | — | — | — | — |
| Gross Profit (Calculated) · Derived | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | — | 16,978,000Source |
| Operating Income (Loss)USD | -29,159,000Source | -102,627,000Source | -15,043,000Source | -60,477,000Source |
| Other Nonoperating Income (Expense)USD | 310,000Source | — | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -33,196,000Source | -67,261,000Source | -8,745,000Source | -139,972,000Source |
| Income Tax Expense (Benefit)USD | -2,553,000Source | -2,680,000Source | -255,000Source | — |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | -123,000Source | -30,593,000Source | -339,000Source | -17,719,000Source |
| Net Income (Loss) Attributable to ParentUSD | -30,520,000Source | -34,410,000Source | -1,876,000Source | -140,547,000Source |
| Earnings Per Share, BasicUSD per share | -1.04Source | -1.45Source | -0.08Source | -6.31Source |
| Earnings Per Share, DilutedUSD per share | -1.04Source | -1.45Source | -0.08Source | -6.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 29,422,221Source | 23,745,516Source | 23,263,211Source | 19,767,342Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 29,422,221Source | 23,745,516Source | 23,263,211Source | 19,767,342Source |
| Additional Financial Items | ||||
| Amortization of Intangible AssetsUSD | 142,000Source | 88,000Source | — | — |
| Business Combination, Acquisition Related CostsUSD | 1,000,000Source | — | — | — |
| Current Income Tax Expense (Benefit)USD | -2,388,000Source | -2,583,000Source | -255,000Source | — |
| Debt Securities, Realized Gain (Loss)USD | 178,000Source | 1,772,000Source | — | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | 288,000Source | 225,000Source | 78,000Source | 72,000Source |
| Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of TaxUSD | — | — | -306,000Source | — |
| Equity Securities, FV-NI, Realized Gain (Loss)USD | — | — | 334,000Source | — |
| Fair Value, Option, Changes in Fair Value, Gain (Loss)USD | 25,000Source | — | — | — |
| Foreign Currency Transaction Gain (Loss), before TaxUSD | — | -53,000Source | -42,000Source | -5,000Source |
| Gain (Loss) on InvestmentsUSD | — | -46,000Source | — | — |
| General and Administrative ExpenseUSD | 13,781,000Source | 8,854,000Source | 8,932,000Source | 17,270,000Source |
| Goodwill, Impairment LossUSD | 3,050,000Source | — | — | — |
| Income (Loss) from Continuing Operations, Net of Tax, Attributable to ParentUSD | — | -65,003,000Source | -8,693,000Source | -140,547,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -32,338,000Source | — | — | -122,828,000Source |
| Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | -8,693,000Source | -140,547,000Source |
| Income (Loss) from Continuing Operations, Per Basic ShareUSD per share | — | -1.45Source | -0.36Source | -6.22Source |
| Income (Loss) from Continuing Operations, Per Diluted ShareUSD per share | — | -1.45Source | -0.36Source | -6.22Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling InterestUSD | — | — | 6,478,000Source | -1,830,000Source |
| Income (Loss) from Discontinued Operations, Net of Tax, Attributable to ParentUSD | — | — | — | 1,830,000Source |
| Income (Loss) from Equity Method InvestmentsUSD | — | — | — | -575,000Source |
| Interest ExpenseUSD | 658,000Source | 248,000Source | — | 6,000Source |
| Interest Expense, DebtUSD | — | — | — | 1,200,000Source |
| Interest Income, OtherUSD | 1,996,000Source | 2,383,000Source | 3,253,000Source | 201,000Source |
| Lease IncomeUSD | 309,000Source | 282,000Source | — | — |
| Marketable Securities, Realized Gain (Loss), Excluding Other-than-temporary Impairment LossUSD | — | 1,772,000Source | 154,000Source | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | -34,410,000Source | -1,876,000Source | -124,658,000Source |
| Noncontrolling Interest in Net Income (Loss) Other Noncontrolling Interests, RedeemableUSD | — | -34,410,000Source | -8,354,000Source | — |
| Other General and Administrative ExpenseUSD | 1,962,000Source | 2,000,000Source | 3,044,000Source | — |
| Other General ExpenseUSD | — | — | — | 157,000Source |
| Other IncomeUSD | — | 118,000Source | — | — |
| Realized Investment Gains (Losses)USD | — | -46,000Source | 309,000Source | — |
| Research and Development ExpenseUSD | 12,823,000Source | 4,170,000Source | 6,312,000Source | 8,742,000Source |
| Selling ExpenseUSD | — | — | 307,913,000Source | — |
Filing attachments
ea030712501ex99-1.htm · 8-K · 2026-09-30
Exhibit 99.1 Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC ™ Study of Trappsol ® Cyclo ™ in Niemann-Pick Disease Type C (NPC) Trappsol® Cyclo™ did not achieve statistical significance but demonstrated a directionally favorable treatment effect versus placebo on the primary endpoint of change in the 4-domain NPC Clinical Severity Scale (4DNPCSS) at Week 96 A prespecified analysis in patients receiving background miglustat and/or leucine therapy, representing a…
Read attachment ↗ea029744201ex99-1.htm · 8-K · 2026-07-08
EX-99.1 2 ea029744201ex99-1.htm INVESTOR PRESENTATION Exhibit 99.1 NYSE: RFL July 2026 | Investor Presentation Forward-Looking Statements Some of the information in this presentation relates to future events or future business and financial performance. Such statements constitute forward-looking information within the meaning of the Private Securities Litigation Act of 1995. Such statements can be only predictions and the actual events or results may differ from those discussed due to, amo…
Read attachment ↗ea029432001ex99-1.htm · 8-K · 2026-06-11
EX-99.1 2 ea029432001ex99-1.htm PRESS RELEASE, DATED JUNE 11, 2026, REPORTING THE RESULTS OF OPERATIONS FOR THE FISCAL QUARTER ENDED APRIL 30, 2026 Exhibit 99.1 Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results NEWARK, NJ - June 11, 2026 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: RFL) today reported its financial results for the third quarter fiscal year 2026 ended April 30, 2026. “Yesterday, we were pleased to announce that we reached the completion of the last pat…
Read attachment ↗ea029415101ex99-1.htm · 8-K · 2026-06-10
EX-99.1 2 ea029415101ex99-1.htm PRESS RELEASE, DATED JUNE 10, 2026 Exhibit 99.1 Rafael Holdings Announces Completion of Last Patient Last Visit for Pivotal Phase 3 TransportNPC ™ Study Evaluating Trappsol ® Cyclo™ for the Treatment of Niemann-Pick Disease Type C Topline results are expected to be announced in second half of calendar 2026 The company has had a pre-NDA meeting with the FDA and expects to submit an NDA in second half of calendar 2026 The company has received acknowledgement…
Read attachment ↗ea028725801ex99-1.htm · 8-K · 2026-04-22
EX-99.1 2 ea028725801ex99-1.htm PRESS RELEASE, DATED APRIL 22, 2026 Exhibit 99.1 Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease” License of the MIT patent strengthens Rafael’s intellectual property around cyclodextrins as an Active Pharmaceutical Ingredient (API) in the treatment of ApoE4-positive Alzheimer’s Disease NEWARK, NJ - April 22, 2026 (GLOBE NEWSWIRE) - Rafael Holdings, Inc. (NYSE: R…
Read attachment ↗